Dr. Philip Toleikis reports
SERNOVA ANNOUNCES RESULTS OF 2018 ANNUAL GENERAL MEETING OF SHAREHOLDERS AND NEW CHIEF FINANCIAL OFFICER
Sernova Corp. received shareholder approval of all management resolutions brought forward at the 2018 annual general meeting held in Vancouver, April 25. In addition, the company is pleased to announce Sean Hodgins, CA, CPA, CPA (Illinois), has joined Sernova as chief financial officer, effective immediately. Mr. Hodgins will work in conjunction with Sernova's chief executive officer in the execution of the company's financial, business development and capital markets strategies, as well as future planned tracking to a U.S. exchange.
"Mr. Hodgins is an experienced biotech executive with both U.S. and Canada corporate background. He is joining Sernova at an important juncture as we embark on our U.S. clinical study and further develop our international business relationships," said Dr. Philip Toleikis, president and CEO, Sernova.
A veteran of the biotechnology industry for over 20 years, Mr. Hodgins is a CA/CPA having earned a bachelor of commerce degree (economics) from the University of British Columbia. He has gained U.S. and Canada experience having tenured at Deloitte LLP in Vancouver and Pricewaterhousecoopers LLP in San Jose, Calif. While in the U.S. he managed two Nasdaq Stock Market initial public offerings and on returning to Canada several Canadian IPOs, as well as serving as CFO for three Toronto Stock Exchange-listed public companies and supporting a number of successful Canadian biotech companies.
Sernova thanks Scott Langille for his contribution as previous CFO and wishes him well in his future endeavours.
Management resolutions at the AGM were approved by an overwhelming majority of shareholders who voted, including election of the directors Frank Holler (chair), James Parsons, Bruce Weber, Jeffrey Bacha and Dr. Philip Toleikis; approval of the stock option plan and amendments; and approval of Davidson and Co. LLP as Sernova's auditor for 2019.
About Sernova Corp.
Sernova is developing disruptive regenerative medical technologies using a medical device (Cell Pouch) and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body.
We seek Safe Harbor.
© 2020 Canjex Publishing Ltd. All rights reserved.